دورية أكاديمية

Interferon Gamma Targeted Therapy: Is It Justified in Primary Sjögren’s Syndrome?

التفاصيل البيبلوغرافية
العنوان: Interferon Gamma Targeted Therapy: Is It Justified in Primary Sjögren’s Syndrome?
المؤلفون: Agata Sebastian, Marta Madej, Paweł Gajdanowicz, Maciej Sebastian, Anna Łuczak, Magdalena Zemelka-Wiącek, Marek Jutel, Piotr Wiland
المصدر: Journal of Clinical Medicine, Vol 11, Iss 18, p 5405 (2022)
بيانات النشر: MDPI AG, 2022.
سنة النشر: 2022
المجموعة: LCC:Medicine
مصطلحات موضوعية: primary Sjögren syndrome, interferon γ, cytokines, Medicine
الوصف: Background: The pathomechanism of primary Sjögren syndrome (pSS) is multifactorial. Many cytokines take part in this process, including interferon. The study aimed to quantify certain cytokines involved in the pathomechanism of primary Sjögren syndrome (IL2, IL5, IL6, IL10, IL13, TNFα, IFNγ) and determine their common clinical correlation. On this basis, we discuss the potential use of anti-cytokine drugs in pSS therapy. Methods: The study group consisted of adult patients with a confirmed diagnosis of pSS. Results: The most frequently detected cytokines were IFNγ (82% of patients), TNFα (70%), IL6 (50%), and IL2 (42.5%). In all patients, except for one patient, IFNγ was found in the presence of other specific cytokines. There was no difference in clinical symptoms, age, and laboratory test results between the group of patients with IL-6 + TNFα + IFNγ positive cytokine, and the group of patients in whom they were not detected. There was no correlation between the presence of IL5, IL13, IL2, IL6, IL10, TNFα and musculoskeletal symptoms, skin lesions, glandular domains, pulmonary neurological, lymphadenopathy, biological and hematological domains in ESSDAI (p > 0.05). Conclusions: IFNγ most likely plays a central role in the pathomechanism of the disease. We have not noticed a clinical correlation between the three most common cytokines (IL6, IFNγ and TNFα), preliminary research results open up the possibility of searching for new treatments for pSS. The lower percentage of patients with detectable levels of TNFα and IL6 may explain the ineffectiveness of drugs targeting cytokines in clinical trials to date.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2077-0383
Relation: https://www.mdpi.com/2077-0383/11/18/5405; https://doaj.org/toc/2077-0383
DOI: 10.3390/jcm11185405
URL الوصول: https://doaj.org/article/e3eb75c3ed50428293aca0b35c54d42a
رقم الأكسشن: edsdoj.3eb75c3ed50428293aca0b35c54d42a
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:20770383
DOI:10.3390/jcm11185405